Phase II evaluation of aclacinomycin-A (NSC-208734) in adenocarcinoma of the kidney.
D015250:Aclarubicin; D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D015250:Aclarubicin